Tao Liu

Tao Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2022 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
JYJinru Yang
Jinru Yang
TLTao Liu
Tao Liu
YZYing Zhu
Ying Zhu
FZFangyuan Zhang
Fangyuan Zhang
MZMenglan Zhai
Menglan Zhai
DYDandan Yu
Dandan Yu
Background: Primary gastric lymphoma (PGL) is the most common extranodal non-Hodgkin lymphoma (NHL). Due to the rarity of the disease, it is important to create a predictive model that provides treatment and prognosis for patients with PGL and physicians. Methods: A total of 8898 and 127 patients diagnosed with PGL were obtained from the SEER database and from our Cancer Center as training and validation cohorts, respectively. Univariate and multivariate Cox proportional hazards models were used to investigate independent risk factors for the construction of predictive survival nomograms, and a web nomogram was developed for the dynamic prediction of survival of patients with PGL. The concordance index (C-index), calibration plot, and receiver operating characteristics (ROC) curve were used to evaluate and validate the nomogram models. Results: There were 8898 PGL patients in the SEER cohort, most of whom were married men over the age of 60, 16.1% of the primary tumors were localized in the antrum and pylori of the stomach, which was similar to the composition of 127 patients in the Chinese cohort, making both groups comparable. The Nomogram of overall survival (OS) was compiled based on eight variables, including age at diagnosis, sex, race, marital status, histology, stage, radiotherapy and chemotherapy. Cancer-specific survival (CSS) nomogram was developed with eight variables, including age at diagnosis, sex, marital status, primary tumor site, histology, stage, radiotherapy and chemotherapy. The C-index of OS prediction nomogram was 0.948 (95% CI: 0.901–0.995) in the validation cohort, the calibration plots showed an optimal match and a high area below the ROC curve (AUC) was observed in both training and validation sets. Also, we established the first web-based PGL survival rate calculator (https://yangjinru.shinyapps.io/DynNomapp/). Conclusion: The web dynamic nomogram provided an insightful and applicable tool for evaluating PGL prognosis in OS and CSS, and can effectively guide individual treatment and monitoring.

11 November 2025 in Oncology Letters
Verified
Journal Article
Open access
PDF file
PLPengye Li
Pengye Li
GAGeraldine Esther Awakossa
Geraldine Esther Awakossa
LZLu Zhou
Lu Zhou
QLQiuhui Li
Qiuhui Li
XLXinxiu Liu
Xinxiu Liu
LZLiling Zhang
Liling Zhang
Natural killer/T‑cell lymphoma (NKTCL) is the most common T‑cell non‑Hodgkin lymphoma in China; however, the clinical characteristics and optimal treatment remain unclear. The present study aimed to retrospectively assess the clinical features of patients with NKTCL and to determine treatment strategies. A total of 200 patients who were diagnosed with NKTCL and admitted to the Cancer Center, Union Hospital (Wuhan, China) between June 2013 and June 2022 were identified. Clinical data from these patients were collected and analyzed to evaluate the clinical features, treatment outcomes and prognostic factors. A total of 171 patients diagnosed with NKTCL were ultimately enrolled. Patients were diagnosed at a median age of 45 years and had a male‑to‑female ratio of 2:1. Out of the 171 patients, 117 were in the early stage (stage I/II; 68.4%) and 54 were in the advanced stage (stage III/IV; 31.6%) of NKTCL. Among these patients, B symptoms were present in 60.2% of patients (103/171) and the Eastern Cooperative Oncology Group performance status was scored as 0‑1 in 93.6% of patients (160/171). Most patients had a low‑to‑moderate risk of international prognostic index (147/171; 86.0%), prognostic index for NKTCL (PINK; 122/171; 71.3%) and PINK with extended features (112/171; 65.5%). At baseline, it was demonstrated that Epstein‑Barr virus DNA was positive in the serum of 166/171 patients (2.9%). Combined chemotherapy and radiotherapy at 54 Gy revealed a promising effect with the highest overall response rate (ORR) of 98.2%, a 4‑year progression‑free survival (PFS) rate of 82.5% [95% confidence interval (CI), 75.1‑89.9%] and an overall survival (OS) rate of 92.2% (95% CI, 86.9‑97.5%) for the early‑stage group. Pegasparase‑based chemotherapy was used to treat advanced‑stage patients, resulting in a 4‑year PFS rate of 62.3% (95% CI, 47.4‑77.2%) and an OS rate of 63.5% (95% CI, 48.2‑78.8%). The regimen containing the programmed cell death protein 1 inhibitor camrelizumab demonstrated an ORR of 100% in both the early‑ and advanced‑stage cohorts. Moreover, stage and an age of >60 years were independent prognostic factors for poor PFS, whilst stage and elevated lactate dehydrogenase were independent prognostic factors for poor OS. In conclusion, the results indicated promising efficacy for pegaspargase‑based chemotherapy in terms of response rates and survival outcomes for both early‑ and advanced‑stage patients. However, further refinement of treatment strategies is needed.